QOL Medical Sells Nascobal

ST. PETERSBURG, FL, April 20,2009 - Ballast Point Ventures ("BPV") is pleased to announce that its Fund I portfolio company, QOL Medical, LLC ("QOL"), has completed a sale of Nascobal(r) (Cyanocobalamin, USP) Nasal Spray ("Nascobal") to Strativa Pharmaceuticals, the branded products division of Par Pharmaceutical Companies, Inc. (NYSE:PRX). Nascobal, acquired by QOL along with two other drugs in October 2005, is an FDA approved prescription nasal spray indicated to treat vitamin B12 deficiency. It is the first and only once-weekly, self-administered alternative to B12 injections. Under the terms of the all cash transaction, Strativa Pharmaceuticals will pay QOL $54.5 million for the worldwide rights to Nascobal Nasal Spray. Ballast Point Ventures and co-investors Pelican Medical, LLC and Conifer Partners, LLC will maintain their ownership positions in QOL, which continues to market three other drugs.

Drew Graham, a QOL director and Managing Partner with BPV, remarked "The successful sale of Nascobal is a testament to the QOL founders' ability to create and harvest substantial value by acquiring under-marketed specialty pharmaceutical products and demonstrating their market potential. Trevor Blake and Edwin Hernandez have done an outstanding job building QOL, and we are excited about both this successful sale and also the company's continued growth prospects." About QOL Medical QOL Medical acquires FDA approved specialty pharmaceuticals and uses its unique operational and marketing model to ensure more people who suffer from rare diseases or rare events have access to medications that can improve their quality of life.

To learn more, contact QOL Medical at 866.469.3773 or visit the website at www.qolmed.com. About Ballast Point Ventures Ballast Point Ventures is a venture capital fund established to provide expansion capital for rapidly growing, privately owned companies in diverse industries, with a particular emphasis on companies located in Florida, the Southeast and Texas. The BPV partners have many years of experience investing in and supporting over 75 high-growth companies in the healthcare, business services, communications, technology, financial services and consumer industries. Ballast Point Ventures has over $180 million under management and seeks to make minority equity investments ranging in size from $3 million to $10 million. For additional information, visit ballastpointventures.com or contact Dick Brandewie, Drew Graham, Paul Johan or Matt Rice